Manchester will be the first region in the UK to adopt central government plans to devolve funding and decision-making powers. In addition to autonomy over housing, skills and transport… a significant £6 billion for health and social care services will be put under local control.
- Autonomy held by 10 local authorities – the ‘Greater Manchester Strategic Partnership’
- Control of health and social care decision-making will therefore sit with local organisations
- Other areas are keen to follow suit across the country, with many discussions in progress (i.e. select London boroughs, Liverpool etc.)
- Manchester will have its own mayor, who will wield considerable influence.
There is split opinion and much debate around the risks and benefits of ‘devo manc’ and the broader impact if other regions follow suit.
- Will social policy have greater influence over pathway design?
- Might this have an impact on the definition and evaluation of cost effectiveness?
- Could this lead to inequitable prescribing between Manchester and the rest of the UK?
- Will there be more political involvement in decisions relating to the NHS?
Ultimately, what impact might this have on the access and uptake of new and existing medicines?
Adelphi has a dedicated NHS consultancy to help you establish what this might mean for your brands
- Spectrum™ payer database with extensive access to payers at all levels
- Spectrum™ payer profiler to tease out nuances by role, ensuring intelligent and targeted recruitment
- A team of expert payer moderators who understand payer phraseology and terminology and the complexities of NHS decision-making to deliver richer insights
To find out more about how this might affect your brand, contact Adelphi’s Market Access Experts: